ybjS Antibody

What is YAbS and what information does it contain?

YAbS (The Antibody Society's Antibody Therapeutics Database) serves as a vital resource for monitoring the development and clinical progress of therapeutic antibodies. The database catalogs detailed information on over 2,900 commercially sponsored investigational antibody candidates that have entered clinical studies since 2000, as well as all approved antibody therapeutics. Data for the late-stage clinical pipeline and antibody therapeutics in regulatory review or approved (over 450 molecules) are openly accessible at https://db.antibodysociety.org. The database includes antibody-related information such as molecular format, targeted antigen, current development status, indications studied, clinical development timeline, and geographical region of company sponsors .

How is YAbS structured and what are its primary data organization principles?

YAbS is structured to enable comprehensive searching, filtering, analyzing, and exporting of antibody therapeutics data. The database offers extensive filtering and search options based on standardized nomenclature, functionality, and architecture for variables including molecular category and format, target antigen, development status, therapeutic area, company sponsor, and country of origin. This standardized structure allows researchers to track both past and upcoming clinical candidates along with their developmental histories .

What makes YAbS different from other antibody databases?

Unlike other public databases, YAbS provides a dedicated page for each antibody candidate with key information about clinical development (e.g., publicly disclosed upcoming events, dates of clinical transitions, clinical trial numbers) and the companies involved in development (e.g., company acquisitions and collaborations). Additionally, the database supports in-depth industry trends analysis, facilitating the identification of innovative developments and the assessment of success rates within the field . YAbS also enables stratified analyses based on molecular characteristics, therapeutic applications, and geographical distribution of development efforts .

What methodologies can be applied to calculate accurate success rates for antibody therapeutics using YAbS?

YAbS contains the most up-to-date status of all publicly disclosed, commercially sponsored antibody therapeutics that were first administered to humans after January 1, 2000, enabling the calculation of accurate success rates for these molecules. Researchers can employ comprehensive methodological approaches by filtering the dataset based on development timelines, molecule types, indications, and endpoints. Several analyses of success rates derived from data in the YAbS database have been previously published, providing methodological frameworks that can be expanded upon for specific research questions .

How can YAbS facilitate the identification of innovative antibody formats in development?

The YAbS database provides detailed molecular data, including general molecular category, targets, formats, Fc and light-chain isotypes, and conjugated components. This enables researchers to perform in-depth analysis and comparison of different antibody candidates. By analyzing trends over time, researchers can identify emerging innovative formats, such as bispecifics and antibody-drug conjugates (ADCs), highlighting evolving strategies in antibody design and application. The database's ability to filter results by time periods and milestone events, such as the start of clinical trials or regulatory submissions, provides valuable insights into the pace of development and regulatory progress of novel antibody formats .

What are the current methodologies for epitope-directed monoclonal antibody production?

Current epitope-directed approaches for monoclonal antibody production address issues of antibody quality, validation, and utility by targeting multiple in silico-predicted epitopes in a single hybridoma production cycle. Short, spatially distant, B-cell epitope-predicted sequences are independently cloned into the surface-exposed loop of a highly soluble His-tagged thioredoxin (Trx) carrier. This facilitates high-yield production and easy purification of bacterially expressed fusion peptides, which are then combined into a mixed immunogen cocktail for animal immunization .

For example, when generating antibodies against human ankyrin repeat domain 1 (hANKRD1), antigenic peptides (13–24 residues long) presented as three-copy inserts on the surface-exposed loop of a thioredoxin carrier produced high affinity mAbs that are reactive to both native and denatured hANKRD1. ELISA assay miniaturization using DEXT microplates allowed rapid hybridoma screening with concomitant epitope identification .

How can researchers effectively map immunogenic epitopes for autoantibody studies?

Systematic analysis for autoantibody formation directed against conformational and linear epitopes within proteins involves several methodological steps. First, generate full-length and truncated recombinant proteins from prokaryotic and eukaryotic cells. Second, characterize spontaneous protein cleavage patterns, which often differ between prokaryotic and eukaryotic systems. Third, detect autoantibodies using human serum samples as "primary" antibodies followed by appropriate secondary detection systems .

For mapping specific immunogenic epitopes, researchers should employ truncated proteins (e.g., GST-fusion constructs) to identify minimum binding regions. Additionally, peptide arrays with consecutive overlapping peptides (e.g., 15mers) can reveal distinct antigenic regions that may differ between patient populations and healthy controls. Protein cleavage assays with recombinant proteins can further characterize how autoantibodies may affect protein stability or function .

What techniques are available for predicting and designing antibody loop structures?

Recent advances in computational methods have enabled highly accurate antibody loop structure prediction, which is crucial for the effective zero-shot design of target-binding antibody loops. The performance of loop design depends on the accuracy of ab initio loop structure prediction, as demonstrated by experiments with different versions of design models. These computational approaches operate without structural templates or related sequences, addressing the challenge of predicting antibody loop structures when lacking evolutionary information from related proteins .

For validation of designed antibody loops, experimental testing should assess high affinity, diversity, novelty, and specificity against target proteins. When designing antibody sequences with customized specificity profiles, researchers can optimize energy functions to either obtain cross-specific sequences (allowing interaction with several distinct ligands) or specific sequences (enabling interaction with a single ligand while excluding others) .

How are bispecific antibodies being developed and evaluated in clinical settings?

Bispecific antibodies represent an important class of therapeutic antibodies that can simultaneously bind two different antigens. When considering bispecific antibody therapy in clinical settings, researchers and clinicians should evaluate several key factors: patient qualification criteria (number of prior treatment lines needed), screening tests required before therapy, and patient-specific health profiles that might preclude bispecific therapy use .

Clinically relevant considerations include differences between FDA-approved bispecific therapies, success rates with specific genetic profiles, and sequencing options after prior bispecific therapy. Clinical trials offer opportunities to access investigational bispecific antibodies, with researchers needing to consider proximity of trial locations and appropriateness of trial participation versus using FDA-approved options .

What methodologies can be employed to develop and characterize novel monoclonal antibodies against specific protein targets?

Development of novel monoclonal antibodies against specific protein targets, such as pathological human TDP-43 proteins, involves several methodological steps. First, generate monoclonal antibodies against bacteria-expressed full-length recombinant proteins. Screen potential clones through indirect ELISA to identify high-affinity antibodies. Perform epitope mapping using different protein fragments designed based on previously reported functional domains to determine binding regions .

Characterization should include multiple validation approaches: detection of endogenous proteins by immunofluorescence and immunoblotting, immunoprecipitation capabilities, immunohistochemistry performance, and suitability for sandwich ELISA development. Some antibodies may show preferential reactivity for pathological protein forms versus normal forms, making them valuable tools for disease-specific investigations .

How can researchers assess antibody responses against multiple viral proteins in infection and vaccination studies?

When studying antibody responses to viral proteins after natural infection or immunization, researchers should examine responses to multiple viral proteins, not just the most commonly studied ones. For example, in SARS-CoV-2 studies, while S and N proteins are extensively studied, examining responses to other viral proteins (E, NS3, etc.) provides a more comprehensive understanding of the immune response .

Methodologically, researchers should measure multiple antibody isotypes (IgG, IgA, IgM) against various viral proteins, examine the correlation between antibody levels and neutralizing activity, and assess cross-reactivity with related viruses. For example, SARS-CoV-2 infection-induced antibodies showed minimal correlation with antibodies against seasonal human coronaviruses, suggesting limited functional cross-reactivity .

What are the common challenges in antibody validation and how can they be addressed using multiple analytical techniques?

Antibody validation faces challenges including variability in specificity, sensitivity, and reproducibility across different applications. A comprehensive validation approach should include multiple techniques: Western blotting to confirm target protein recognition at the expected molecular weight, immunoprecipitation to verify native protein binding, immunohistochemistry/immunocytochemistry to assess cellular localization patterns, and ELISA to quantify binding affinity .

Researchers should be aware that the observed molecular weight may not always match theoretical predictions due to post-translational modifications, protein complexes, or technical factors affecting protein mobility. For example, YB-1/YBX1 antibodies may detect a 50 kDa band rather than the calculated 35 kDa, potentially due to protein modifications . Multiple antibodies targeting different epitopes of the same protein should be used for cross-validation, especially for studies of novel or controversial protein functions.

How should researchers interpret antibody test results in clinical and research settings?

For research applications, particularly when studying autoantibodies, researchers should compare results between patient populations and appropriate controls, consider isotype-specific responses (IgG vs. IgM vs. IgE), and evaluate epitope specificity. Differences in binding to prokaryotic versus eukaryotic expressed proteins can provide insights into conformational epitope recognition. Additionally, researchers should consider how antibodies might affect protein function or stability, as demonstrated in studies where cancer patient sera containing autoantibodies extended the half-life of target proteins .

What statistical approaches are most appropriate for analyzing large-scale antibody data from YAbS?

When analyzing large-scale antibody data from YAbS, researchers should employ statistical approaches that account for the complex, multidimensional nature of the dataset. For trend analysis over time, time-series statistical methods can identify significant patterns in antibody development strategies. Multivariate analysis techniques can help identify correlations between molecular characteristics, therapeutic areas, and development outcomes .

For success rate calculations, survival analysis methods (such as Kaplan-Meier estimates and Cox proportional hazards models) are appropriate for handling the time-dependent nature of clinical development progression. When comparing different antibody categories or therapeutic areas, appropriate statistical tests should be selected based on data distribution and study questions. Visualization techniques such as those demonstrated in the YAbS use cases can effectively communicate complex relationships within the data .